Your browser doesn't support javascript.
loading
Best practices for the use of intracerebroventricular drug delivery devices.
Slavc, Irene; Cohen-Pfeffer, Jessica L; Gururangan, Sridharan; Krauser, Jeanne; Lim, Daniel A; Maldaun, Marcos; Schwering, Christoph; Shaywitz, Adam J; Westphal, Manfred.
Afiliação
  • Slavc I; Medical University of Vienna, Department of Pediatrics and Adolescent Medicine, Vienna, Austria. Electronic address: irene.slavc@meduniwien.ac.at.
  • Cohen-Pfeffer JL; BioMarin Pharmaceutical Inc., Novato, CA, USA.
  • Gururangan S; McKnight Brain Institute, University of Florida, Gainsville, FL, USA.
  • Krauser J; McKnight Brain Institute, University of Florida, Gainsville, FL, USA.
  • Lim DA; University of California, San Francisco, CA, USA.
  • Maldaun M; IEP-Hospital Sírio-Libanês, São Paulo, Brazil.
  • Schwering C; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Shaywitz AJ; BioMarin Pharmaceutical Inc., Novato, CA, USA.
  • Westphal M; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mol Genet Metab ; 124(3): 184-188, 2018 07.
Article em En | MEDLINE | ID: mdl-29793829
For decades, intracerebroventricular (ICV), or intraventricular, devices have been used in the treatment of a broad range of pediatric and adult central nervous system (CNS) disorders. Due to the limited permeability of the blood brain barrier, diseases with CNS involvement may require direct administration of drugs into the brain to achieve full therapeutic effect. A recent comprehensive literature review on the clinical use and complications of ICV drug delivery revealed that device-associated complication rates are variable, and may be as high as 33% for non-infectious complications and 27% for infectious complications. The variability in reported safety outcomes may be driven by a lack of consensus on best practices of device use. Numerous studies have demonstrated that employing strict aseptic techniques and following stringent protocols can dramatically reduce complications. Key practices to be considered in facilitating the safe, long-term use of these devices are presented.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos do Sistema Nervoso Central / Doenças do Sistema Nervoso Central / Sistemas de Liberação de Medicamentos / Guias de Prática Clínica como Assunto / Injeções Intraventriculares Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos do Sistema Nervoso Central / Doenças do Sistema Nervoso Central / Sistemas de Liberação de Medicamentos / Guias de Prática Clínica como Assunto / Injeções Intraventriculares Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article